Explore
Challenges and Opportunities for Effective Cancer Immunotherapies
0 Ungluers have
Faved this Work
Login to Fave
Anti-cancer immunotherapies have generated spectacular outcomes in the clinical environment and changed treatment schemes for cancer patients. Adoptive cell therapies (ACTs), including using autologous tumor-infiltrating lymphocytes and chimeric antigen receptor (CAR) T cells, and checkpoint blockades have emerged as the most effective treatments for certain cancers. The current challenge for cancer immunotherapies is that although some patients have benefited from the treatments, a number of cancers are resistant. The purpose of this Special Issue is to understand anti-cancer immunotherapy treatment resistance mechanisms and explore new options to provide opportunities for effective treatments.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 38 times via unglue.it ebook links.
- 38 - pdf (CC BY) at Unglue.it.
Keywords
- adipose tissue-derived stem cells (ADSCs)
- adoptive cell therapy
- adoptive cell transfer
- animal model
- anti-cancer therapies
- anti-tumor immunity
- antibody therapy
- antigen processing and presentation
- Axl
- B cell
- Biomimicry
- Breast cancer
- Cancer
- cancer immunotherapy
- CAR T cell therapy
- CAR T cells
- CAR-T cell therapy
- CD19
- CD3-bispecific antibody
- CD44
- CD8 coreceptor
- Cell Cycle
- cervical cancer
- Checkpoint inhibitors
- chemotherapy
- chimeric antigen receptor
- chimeric antigen receptor (CAR) T cell (CAR-T)
- Clinical Trial
- clinical trials
- combination therapy
- convergent evolution
- cross-priming
- CRS
- dendritic cell
- dendritic cell vaccination
- Dendritic Cells
- endodomain
- Flt3
- Flt3L
- GBM
- Gene Therapy
- Glioblastoma
- HER2-positive
- histon (de)acetylation
- IL-12 family cytokines
- immune cell
- immune checkpoint blockade
- immune checkpoint inhibitor
- immune checkpoint inhibitors
- immune checkpoint molecules
- Immune Evasion
- Immune response
- immuno-oncology
- immunocyte membrane-coated nanoparticles
- immunogenicity
- Immunotherapy
- individualized multimodal immunotherapy
- Interleukin-15
- intratumoural
- local ablation therapies
- macrophage
- major histocompatibility complex
- medicine
- Melanoma
- memory T cell
- MerTK
- mesenchymal stem cells
- metabolic reprogramming
- microenvironment
- Mitochondria
- Model
- modulated electrohyperthermia
- monoclonal antibodies
- Monoclonal antibody
- murine
- myxoma virus
- n/a
- natural killer
- near infrared photoimmunotherapy
- Newcastle disease virus
- NK cell immunosurveillance
- NK cells
- NKG2D
- NKG2D ligands
- NKG2D receptor
- nonreplicating adenovirus vector
- oligomerization
- on-target off-tumor toxicity
- Oncolytic Virotherapy
- oncolytic virus
- pancreatic ductal adenocarcinoma
- pancreatic tumor
- pattern-recognition receptors
- PD-1
- PD-1/PD-L1
- pembrolizumab
- preclinical
- protein kinase inhibitors
- Radiotherapy
- recurrence
- ROPN1
- ROPN1B
- Ropporin-1
- Ropporin-1B
- routes of delivery
- signal transduction
- signaling kinetics
- small molecule inhibitors
- solid tumors
- stat
- T cell
- T cell metabolism
- T cell receptor
- T lymphocyte
- T-cell
- T-cell co-stimulation
- T-cell engager
- TAM receptors
- targeted therapy
- TNFα
- Toll-Like Receptors
- Toxicity
- Tumor microenvironment
- tumor-associated antigens
- Tumor-infiltrating lymphocytes
- tumor-specific antigen
- tumour antigens
- tumour microenvironment
- virus coated with cancer cell membrane
- Viruses
Links
DOI: 10.3390/books978-3-0365-6961-1Editions